Aerosolized chemically modified tetracycline nanoformulation for the treatment of acute respiratory distress syndrome

This study is a joint-industry (funded by a Phase I/II Fast-Track) project with CMTx Biotech. CMTx Biotech have a chemically modified tetracycline that is effective at attenuating sepsis-associated lung injury through NLRP3 inflammasome and matrix metalloproteinase pathways [Meng Shock 2022]. It has marked anti-inflammatory effects but has, until recently, only been available in an oral form. This project studies a novel nanoformulation that can be aerosolized to determine if it can modify inflammation-mediated lung injury in a 48-hour model of sepsis.